Estrella Immunopharma, Inc. (ESLA)

Estrella Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	1.8	4.17	2.48	4.09	-
Cash & Short-Term Investments	1.8	4.17	2.48	4.09	-
Cash Growth	-91.88%	68.02%	-39.36%	-	-
Receivables	-	-	0.27	-	-
Prepaid Expenses	0.44	0.29	-	0.83	-
Total Current Assets	2.24	4.45	2.75	4.92	-
Long-Term Deferred Charges	-	-	0.28	-	-
Total Assets	3.74	4.45	3.03	4.92	-
Accrued Expenses	2.94	0.14	8.85	0.03	-
Current Portion of Leases	0	0	0.02	-	-
Current Income Taxes Payable	0.04	0.04	-	-	-
Other Current Liabilities	0	0	0.88	0.92	-
Total Current Liabilities	2.99	0.18	9.76	0.95	-
Other Long-Term Liabilities	-	-	0.01	0.01	-
Total Liabilities	2.99	0.18	9.77	0.96	-
Common Stock	0	0	0	0	-
Additional Paid-In Capital	24.12	24.12	0.45	0.03	-
Retained Earnings	-22.88	-19.5	-12.19	-1.07	-
Treasury Stock	-0.5	-0.35	-	-	-
Total Common Equity	0.75	4.27	-11.74	-1.04	-
Shareholders' Equity	0.75	4.27	-6.74	3.96	-
Total Liabilities & Equity	3.74	4.45	3.03	4.92	-
Total Debt	0	0	0.02	-	-
Net Cash (Debt)	1.79	4.16	2.46	4.09	-
Net Cash Growth	-91.78%	69.36%	-39.90%	-	-
Net Cash Per Share	0.05	0.15	8.04	-	-
Filing Date Shares Outstanding	36.18	36.19	35.2	0.18	-
Total Common Shares Outstanding	36.18	36.29	4.06	0.18	-
Working Capital	-0.75	4.27	-7.01	3.97	-
Book Value Per Share	0.02	0.12	-2.89	-5.91	-
Tangible Book Value	0.75	4.27	-11.74	-1.04	-
Tangible Book Value Per Share	0.02	0.12	-2.89	-5.91	-

Source: S&P Capital IQ. Standard template. Financial Sources.